Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

07 January 2021

Visiongain has launched a new report Inactivated Vaccines Market Report 2020-2030: Forecasts by Pathogen Type (Viral, Bacterial), by Target Type (Pertussis, Cholera, Polio (IPV), Influenza, Hepatitis A, Cell Mediated Rabies, Others), by End-user Type (Paediatric, Adults), by Channel Type (Hospitals & Clinics, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Inactivated Vaccines Companies AND COVID-19 Recovery Scenarios.

Global Inactivate Vaccines market was valued at US$ xx billion in 2019 and is projected to reach at a market value of US$xx billion by 2030. Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

COVID-19 Impact on Inactivated Vaccines Market
The emergence of COVID-19 event has affected to greater extent to the growth of this market as inactivated vaccines plays a major role in the production process of new upcoming vaccines, as government across all countries are strengthening their health and related services to combat against COVID-19 outbreak. Four parameters has helps this market to regain the growth without losing growth momentum during this COVID-19 situation. This mainly includes vaccine procurement, manufacturing, R&D, and vaccination coverage.

Market Drivers

Rise in prevalence of infectious diseases
Increasing prevalence of infectious disease is causing a real time threat to public health in almost all the countries. Cholera, Influenza, Hepatitis A, Polio, and Pertussis are some of the mainly observed infectious diseases across the globe and prevalence rate for these diseases is growing significantly. Inactivated vaccines are effectively used to treat above-mentioned diseases and therefore growing incidences of these diseases is driving the growth of this market.

Government support in vaccine development
Government support has been playing major role in the vaccine innovation and development in response to the vital role played by vaccines in the healthcare practices. To ensure public health, governments from various geographies have been coming up with measures to offer opportunities in vaccine innovations. Such initiatives are seen to be relatively organized in developed countries like U.S. and few European countries. U.S. government has come up with ‘National Vaccine plan’ with a vision of developing new and improved vaccines. The aim of this plan is to prioritize new vaccine targets of domestic and global public health importance, support research to develop and manufacture new vaccine candidates and improve current vaccines to prevent infectious diseases, and support research on novel and improved vaccine delivery methods.

Market Opportunities

Demand for vaccines during Corona pandemic
Amid COVID-19, demand for inactivated vaccines has increased as inactivated vaccines are having lower disadvantages compared to activated vaccines. There is currently no treatment available for the disease. However, vaccination is the key for controlling the spread of Covid19 strains. Healthcare authorities across are awareness about the need of vaccine and are now prioritizing the demand for vaccine. This is due to a rapid increase in number of corona cases and rising death tolls due to the diseases.

Competitive Landscape
Some of the companies profiled in the report include GlaxoSmithKline PLC, Emergent BioSolutions Inc., Merck & Co., Inc., Sanofi, Valneva SE, Pfizer, Astellas Pharma Inc., Johnson & Johnson, Seqirus Serum Institute of India, and range of other players. The vaccine industry is becoming one of the largest and profits making industry with a presence of many global and regional players. Therefore, the market is highly competitive in nature. Strong competition is due to high importance of intellectual property of leading researchers in the market. Any new vaccine has its public information analysed to evaluate the possibility of creating similar vaccine as substitute. The global inactivated vaccine market and the global pharmaceutical industry is controlled by manufacturers that have promising research pipeline which is ultimately increasing degree of competition in the market.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021


Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021


Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021


Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021